These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models. Guo Q; Chan JF; Poon VK; Wu S; Chan CC; Hou L; Yip CC; Ren C; Cai JP; Zhao M; Zhang AJ; Song X; Chan KH; Wang B; Kok KH; Wen Y; Yuen KY; Chen W J Infect Dis; 2018 Jul; 218(3):365-377. PubMed ID: 29617816 [TBL] [Abstract][Full Text] [Related]
7. Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines. Kim SH; Samal SK Viruses; 2016 Jul; 8(7):. PubMed ID: 27384578 [TBL] [Abstract][Full Text] [Related]
8. Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates. Tang A; Freed DC; Li F; Meschino S; Prokop M; Bett A; Casimiro D; Wang D; Fu TM Hum Vaccin Immunother; 2017 Dec; 13(12):2763-2771. PubMed ID: 28494195 [TBL] [Abstract][Full Text] [Related]
10. New technologies in developing recombinant attenuated Salmonella vaccine vectors. Wang S; Kong Q; Curtiss R Microb Pathog; 2013 May; 58():17-28. PubMed ID: 23142647 [TBL] [Abstract][Full Text] [Related]
11. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Seregin SS; Amalfitano A Expert Opin Biol Ther; 2009 Dec; 9(12):1521-31. PubMed ID: 19780714 [TBL] [Abstract][Full Text] [Related]
12. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865 [TBL] [Abstract][Full Text] [Related]
13. Future Prospects for the Development of Cost-Effective Adenovirus Vaccines. Fougeroux C; Holst PJ Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28420073 [TBL] [Abstract][Full Text] [Related]
14. Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Zakhartchouk AN; Reddy PS; Baxi M; Baca-Estrada ME; Mehtali M; Babiuk LA; Tikoo SK Virology; 1998 Oct; 250(1):220-9. PubMed ID: 9770436 [TBL] [Abstract][Full Text] [Related]
15. Recombinant vaccine delivery systems and encoded vaccines. Stover CK Curr Opin Immunol; 1994 Aug; 6(4):568-71. PubMed ID: 7946044 [TBL] [Abstract][Full Text] [Related]
16. Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines. Singh S; Vedi S; Samrat SK; Li W; Kumar R; Agrawal B PLoS One; 2016; 11(1):e0146404. PubMed ID: 26751211 [TBL] [Abstract][Full Text] [Related]
17. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B. Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900 [TBL] [Abstract][Full Text] [Related]
18. Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases. Zhang J; Tarbet EB; Toro H; Tang DC Expert Rev Vaccines; 2011 Nov; 10(11):1539-52. PubMed ID: 22043954 [TBL] [Abstract][Full Text] [Related]